APO Research
Talk to an analyst

APO RESEARCH · REPORT

Covid-19 Treatment

Patients today have more treatment options in the battle against coronavirus disease.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Patients today have more treatment options in the battle against coronavirus disease.

In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.

The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.

The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.

In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.

In this report, we study all treatment method for Covid-19.

Selected research

Market Outlook & Growth Opportunities

Global Covid-19 Treatment Market Outlook and Growth Opportunities 2026

28 December 2025203 pages

Choose your research edition.

Industry ResearchCovid-19 Treatment Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Covid-19 Treatment Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Covid-19 Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Covid-19 Treatment Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Covid-19 Treatment Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

Patients today have more treatment options in the battle against coronavirus disease.

In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.

The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.

Read the full market overview

The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.

In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.

In this report, we study all treatment method for Covid-19.

Global core covid-19 treatment manufacturers include Cadila Healthcare, Novartis etc.The top 2 companies hold a share about 30%.North America is the largest market, with a share about 47%, followed by Europe and Asia Pacific with the share about 30% and 9%.

This report provides an overview of the global Covid-19 Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Covid-19 Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Covid-19 Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Covid-19 Treatment market.

Covid-19 Treatment Segment by Company

Cadila Healthcare

Johnson & Johnson

ImmunoPrecise

Novartis

AstraZeneca

Cipla

AbbVie

Bayer

Regeneron Pharmaceuticals

Ascletis Pharma

GlaxoSmithKline

Gilead Sciences

Pharmstandard

Fujifilm Holdings

Zhejiang Hisun Pharmaceutical Co. Ltd

Roche

Sanofi

Pfizer

Eli Lilly

Covid-19 Treatment Segment by Type

Life Support

Antiviral Medicine

Antibody Treatments

Others

Covid-19 Treatment Segment by End User

Children

Adult

Covid-19 Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Covid-19 Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Covid-19 Treatment key companies, revenue, market share, and recent developments.

3. To split the Covid-19 Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Covid-19 Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Covid-19 Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Covid-19 Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Covid-19 Treatment industry.

Chapter 3: Detailed analysis of Covid-19 Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Covid-19 Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Covid-19 Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Covid-19 Treatment Industry Trends Table 2. Covid-19 Treatment Industry Drivers Table 3. Covid-19 Treatment Industry Opportunities and Challenges Table 4. Covid-19 Treatment Industry Restraints Table 5. Global Covid-19 Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Covid-19 Treatment Revenue Share by Company (2021-2026) Table 7. Global Covid-19 Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Covid-19 Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Covid-19 Treatment Company, Product Type & Application Table 10. Global Covid-19 Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Covid-19 Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Life Support Table 15. Significant Companies of Antiviral Medicine Table 16. Significant Companies of Antibody Treatments Table 17. Significant Companies of Others Table 18. Global Covid-19 Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Covid-19 Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Covid-19 Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Covid-19 Treatment Sales Value Share by Type (2021-2026) Table 22. Global Covid-19 Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Children Table 24. Significant Companies of Adult Table 25. Global Covid-19 Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Covid-19 Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Covid-19 Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Covid-19 Treatment Sales Value Share by Application (2021-2026) Table 29. Global Covid-19 Treatment Sales Value Share by Application (2027-2032) Table 30. Global Covid-19 Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Covid-19 Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Covid-19 Treatment Sales Value Share by Region (2021-2026) Table 33. Global Covid-19 Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Covid-19 Treatment Sales Value Share by Region (2027-2032) Table 35. Global Covid-19 Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Covid-19 Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Covid-19 Treatment Sales Value Market Share by Country (2021-2026) Table 38. Global Covid-19 Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Covid-19 Treatment Sales Value Market Share by Country (2027-2032) Table 40. Cadila Healthcare Company Information Table 41. Cadila Healthcare Business Overview Table 42. Cadila Healthcare Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Cadila Healthcare Covid-19 Treatment Product Portfolio Table 44. Cadila Healthcare Recent Development Table 45. Johnson & Johnson Company Information Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Johnson & Johnson Covid-19 Treatment Product Portfolio Table 49. Johnson & Johnson Recent Development Table 50. ImmunoPrecise Company Information Table 51. ImmunoPrecise Business Overview Table 52. ImmunoPrecise Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. ImmunoPrecise Covid-19 Treatment Product Portfolio Table 54. ImmunoPrecise Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Novartis Covid-19 Treatment Product Portfolio Table 59. Novartis Recent Development Table 60. AstraZeneca Company Information Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. AstraZeneca Covid-19 Treatment Product Portfolio Table 64. AstraZeneca Recent Development Table 65. Cipla Company Information Table 66. Cipla Business Overview Table 67. Cipla Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Cipla Covid-19 Treatment Product Portfolio Table 69. Cipla Recent Development Table 70. AbbVie Company Information Table 71. AbbVie Business Overview Table 72. AbbVie Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. AbbVie Covid-19 Treatment Product Portfolio Table 74. AbbVie Recent Development Table 75. Bayer Company Information Table 76. Bayer Business Overview Table 77. Bayer Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Bayer Covid-19 Treatment Product Portfolio Table 79. Bayer Recent Development Table 80. Regeneron Pharmaceuticals Company Information Table 81. Regeneron Pharmaceuticals Business Overview Table 82. Regeneron Pharmaceuticals Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Regeneron Pharmaceuticals Covid-19 Treatment Product Portfolio Table 84. Regeneron Pharmaceuticals Recent Development Table 85. Ascletis Pharma Company Information Table 86. Ascletis Pharma Business Overview Table 87. Ascletis Pharma Covid-19 Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Ascletis Pharma Covid-19 Treatment Product Portfolio Table 89. Ascletis Pharma Recent Development Table 90. GlaxoSmithKline Company Information Table 91. GlaxoSmithKline Business Overview Table 92. GlaxoSmithKline Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GlaxoSmithKline Covid-19 Treatment Product Portfolio Table 94. GlaxoSmithKline Recent Development Table 95. Gilead Sciences Company Information Table 96. Gilead Sciences Business Overview Table 97. Gilead Sciences Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Gilead Sciences Covid-19 Treatment Product Portfolio Table 99. Gilead Sciences Recent Development Table 100. Pharmstandard Company Information Table 101. Pharmstandard Business Overview Table 102. Pharmstandard Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Pharmstandard Covid-19 Treatment Product Portfolio Table 104. Pharmstandard Recent Development Table 105. Fujifilm Holdings Company Information Table 106. Fujifilm Holdings Business Overview Table 107. Fujifilm Holdings Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Fujifilm Holdings Covid-19 Treatment Product Portfolio Table 109. Fujifilm Holdings Recent Development Table 110. Zhejiang Hisun Pharmaceutical Co. Ltd Company Information Table 111. Zhejiang Hisun Pharmaceutical Co. Ltd Business Overview Table 112. Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Product Portfolio Table 114. Zhejiang Hisun Pharmaceutical Co. Ltd Recent Development Table 115. Roche Company Information Table 116. Roche Business Overview Table 117. Roche Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Roche Covid-19 Treatment Product Portfolio Table 119. Roche Recent Development Table 120. Sanofi Company Information Table 121. Sanofi Business Overview Table 122. Sanofi Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Sanofi Covid-19 Treatment Product Portfolio Table 124. Sanofi Recent Development Table 125. Pfizer Company Information Table 126. Pfizer Business Overview Table 127. Pfizer Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Pfizer Covid-19 Treatment Product Portfolio Table 129. Pfizer Recent Development Table 130. Eli Lilly Company Information Table 131. Eli Lilly Business Overview Table 132. Eli Lilly Covid-19 Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Eli Lilly Covid-19 Treatment Product Portfolio Table 134. Eli Lilly Recent Development Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Covid-19 Treatment Product Image Figure 2. Global Covid-19 Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Covid-19 Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Covid-19 Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Life Support Image Figure 8. Antiviral Medicine Image Figure 9. Antibody Treatments Image Figure 10. Others Image Figure 11. Global Covid-19 Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Covid-19 Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Covid-19 Treatment Sales Value Share by Type (2021-2032) Figure 14. Children Image Figure 15. Adult Image Figure 16. Global Covid-19 Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Covid-19 Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Covid-19 Treatment Sales Value Share by Application (2021-2032) Figure 19. Global Covid-19 Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Covid-19 Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Covid-19 Treatment Sales Value (2021-2032) & (US$ Million) Figure 22. North America Covid-19 Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Covid-19 Treatment Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Covid-19 Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Covid-19 Treatment Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Covid-19 Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Covid-19 Treatment Sales Value (2021-2032) & (US$ Million) Figure 28. South America Covid-19 Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Covid-19 Treatment Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Covid-19 Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Covid-19 Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Life Support
  • Antiviral Medicine
  • Antibody Treatments
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Cadila Healthcare
  • Johnson & Johnson
  • ImmunoPrecise
  • Novartis
  • AstraZeneca
  • Cipla
  • AbbVie
  • Bayer
  • Regeneron Pharmaceuticals
  • Ascletis Pharma
  • GlaxoSmithKline
  • Gilead Sciences
  • Pharmstandard
  • Fujifilm Holdings
  • Zhejiang Hisun Pharmaceutical Co. Ltd
  • Roche
  • Sanofi
  • Pfizer
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Covid-19 Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Covid-19 Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Covid-19 Treatment Market Dynamics
  1. 2.1 Covid-19 Treatment Industry Trends
  2. 2.2 Covid-19 Treatment Industry Drivers
  3. 2.3 Covid-19 Treatment Industry Opportunities and Challenges
  4. 2.4 Covid-19 Treatment Industry Restraints
3 Covid-19 Treatment Market by Company
  1. 3.1 Global Covid-19 Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Covid-19 Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Covid-19 Treatment Company Ranking (2024-2026)
  4. 3.4 Global Covid-19 Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Covid-19 Treatment Company Product Type and Application
  6. 3.6 Global Covid-19 Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Covid-19 Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Covid-19 Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Covid-19 Treatment Market by Type
  1. 4.1 Covid-19 Treatment Type Introduction
  2. 4.1.1 Life Support
  3. 4.1.2 Antiviral Medicine
  4. 4.1.3 Antibody Treatments
  5. 4.1.4 Others
  6. 4.2 Global Covid-19 Treatment Sales Value by Type
  7. 4.2.1 Global Covid-19 Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Covid-19 Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Covid-19 Treatment Sales Value Share by Type (2021-2032)
5 Covid-19 Treatment Market by Application
  1. 5.1 Covid-19 Treatment Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Covid-19 Treatment Sales Value by Application
  5. 5.2.1 Global Covid-19 Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Covid-19 Treatment Sales Value by Application (2021-2032)
  7. 5.2.3 Global Covid-19 Treatment Sales Value Share by Application (2021-2032)
6 Covid-19 Treatment Regional Value Analysis
  1. 6.1 Global Covid-19 Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Covid-19 Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Covid-19 Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Covid-19 Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Covid-19 Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Covid-19 Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Covid-19 Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Covid-19 Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Covid-19 Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Covid-19 Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Covid-19 Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Covid-19 Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Covid-19 Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Covid-19 Treatment Sales Value Share by Country, 2025 VS 2032
7 Covid-19 Treatment Country-level Value Analysis
  1. 7.1 Global Covid-19 Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Covid-19 Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Covid-19 Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Covid-19 Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Covid-19 Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Covid-19 Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Covid-19 Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Cadila Healthcare
  2. 8.1.1 Cadila Healthcare Company Information
  3. 8.1.2 Cadila Healthcare Business Overview
  4. 8.1.3 Cadila Healthcare Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Cadila Healthcare Covid-19 Treatment Product Portfolio
  6. 8.1.5 Cadila Healthcare Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Covid-19 Treatment Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 ImmunoPrecise
  14. 8.3.1 ImmunoPrecise Company Information
  15. 8.3.2 ImmunoPrecise Business Overview
  16. 8.3.3 ImmunoPrecise Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 ImmunoPrecise Covid-19 Treatment Product Portfolio
  18. 8.3.5 ImmunoPrecise Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Covid-19 Treatment Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Covid-19 Treatment Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 Cipla
  32. 8.6.1 Cipla Company Information
  33. 8.6.2 Cipla Business Overview
  34. 8.6.3 Cipla Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cipla Covid-19 Treatment Product Portfolio
  36. 8.6.5 Cipla Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Covid-19 Treatment Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Bayer
  44. 8.8.1 Bayer Company Information
  45. 8.8.2 Bayer Business Overview
  46. 8.8.3 Bayer Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bayer Covid-19 Treatment Product Portfolio
  48. 8.8.5 Bayer Recent Developments
  49. 8.9 Regeneron Pharmaceuticals
  50. 8.9.1 Regeneron Pharmaceuticals Company Information
  51. 8.9.2 Regeneron Pharmaceuticals Business Overview
  52. 8.9.3 Regeneron Pharmaceuticals Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Regeneron Pharmaceuticals Covid-19 Treatment Product Portfolio
  54. 8.9.5 Regeneron Pharmaceuticals Recent Developments
  55. 8.10 Ascletis Pharma
  56. 8.10.1 Ascletis Pharma Company Information
  57. 8.10.2 Ascletis Pharma Business Overview
  58. 8.10.3 Ascletis Pharma Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ascletis Pharma Covid-19 Treatment Product Portfolio
  60. 8.10.5 Ascletis Pharma Recent Developments
  61. 8.11 GlaxoSmithKline
  62. 8.11.1 GlaxoSmithKline Company Information
  63. 8.11.2 GlaxoSmithKline Business Overview
  64. 8.11.3 GlaxoSmithKline Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline Covid-19 Treatment Product Portfolio
  66. 8.11.5 GlaxoSmithKline Recent Developments
  67. 8.12 Gilead Sciences
  68. 8.12.1 Gilead Sciences Company Information
  69. 8.12.2 Gilead Sciences Business Overview
  70. 8.12.3 Gilead Sciences Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Sciences Covid-19 Treatment Product Portfolio
  72. 8.12.5 Gilead Sciences Recent Developments
  73. 8.13 Pharmstandard
  74. 8.13.1 Pharmstandard Company Information
  75. 8.13.2 Pharmstandard Business Overview
  76. 8.13.3 Pharmstandard Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Pharmstandard Covid-19 Treatment Product Portfolio
  78. 8.13.5 Pharmstandard Recent Developments
  79. 8.14 Fujifilm Holdings
  80. 8.14.1 Fujifilm Holdings Company Information
  81. 8.14.2 Fujifilm Holdings Business Overview
  82. 8.14.3 Fujifilm Holdings Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Fujifilm Holdings Covid-19 Treatment Product Portfolio
  84. 8.14.5 Fujifilm Holdings Recent Developments
  85. 8.15 Zhejiang Hisun Pharmaceutical Co. Ltd
  86. 8.15.1 Zhejiang Hisun Pharmaceutical Co. Ltd Company Information
  87. 8.15.2 Zhejiang Hisun Pharmaceutical Co. Ltd Business Overview
  88. 8.15.3 Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Product Portfolio
  90. 8.15.5 Zhejiang Hisun Pharmaceutical Co. Ltd Recent Developments
  91. 8.16 Roche
  92. 8.16.1 Roche Company Information
  93. 8.16.2 Roche Business Overview
  94. 8.16.3 Roche Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Roche Covid-19 Treatment Product Portfolio
  96. 8.16.5 Roche Recent Developments
  97. 8.17 Sanofi
  98. 8.17.1 Sanofi Company Information
  99. 8.17.2 Sanofi Business Overview
  100. 8.17.3 Sanofi Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Covid-19 Treatment Product Portfolio
  102. 8.17.5 Sanofi Recent Developments
  103. 8.18 Pfizer
  104. 8.18.1 Pfizer Company Information
  105. 8.18.2 Pfizer Business Overview
  106. 8.18.3 Pfizer Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Pfizer Covid-19 Treatment Product Portfolio
  108. 8.18.5 Pfizer Recent Developments
  109. 8.19 Eli Lilly
  110. 8.19.1 Eli Lilly Company Information
  111. 8.19.2 Eli Lilly Business Overview
  112. 8.19.3 Eli Lilly Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Eli Lilly Covid-19 Treatment Product Portfolio
  114. 8.19.5 Eli Lilly Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst